30 Years of M&A Expertise Joins the Boardroom: Jason Bernhard’s Lazard Experience to Guide Acadia Healthcare Through Investor Pressure
Acadia Healthcare, a prominent player in the behavioral health care sector, has welcomed Jason Bernhard to its board of directors. His appointment, which took place in December 2019, marks a significant move for the company as it seeks to enhance its strategic direction amidst industry challenges and growing shareholder expectations. With over 30 years of experience in healthcare investment banking, Bernhard’s background aligns seamlessly with Acadia’s mission to provide high-quality behavioral health services.
Jason Bernhard currently serves as the Chief Operating Officer of Financial Advisory North America at Lazard, where he has been a key figure for more than two decades. His leadership extends to his role as Managing Director and Head of North America Healthcare Investment Banking at Lazard, where he has been instrumental in developing the firm’s healthcare initiatives, including its biotechnology and healthcare services practices. Bernhard’s deep understanding of corporate finance, particularly in the healthcare sector, underscores his potential to contribute meaningfully to Acadia Healthcare’s strategic priorities.
The board of Acadia Healthcare now stands at eight members, bolstered by Bernhard’s expertise in mergers, acquisitions, and corporate finance transactions. His previous roles include Vice President of Mergers and Acquisitions at Citigroup and analyst/associate positions at Merrill Lynch across major global financial hubs such as New York, London, and Hong Kong. This diverse experience equips Bernhard with a unique perspective on navigating the complexities of the healthcare landscape, both domestically and internationally.
Reeve Waud, Chairman of Acadia’s board, expressed enthusiasm for Bernhard’s addition, highlighting the value his insights will bring as the company aims to enhance long-term and sustainable shareholder value. This sentiment is particularly pertinent as Acadia navigates challenges, including a recently declared 7.3 percent stake by New York investment firm P2 Capital Partners. The firm has indicated its intention to engage with Acadia’s management to explore strategies that would maximize shareholder value, a move that underscores the urgency for effective financial stewardship.
Under the leadership of CEO Debbie Osteen, Acadia Healthcare is also considering strategic options, including the potential divestiture of its $1.1 billion UK operations acquired in 2016. This decision comes in the wake of fluctuating share prices, with Acadia’s stock (Ticker: ACHC) experiencing a decline of over 20 percent during late summer, followed by a gradual recovery. In light of these developments, Bernhard’s financial acumen will be critical in guiding the company through this transitional phase.
As Acadia Healthcare continues to adapt to the evolving healthcare environment, the insights of seasoned professionals like Jason Bernhard will be invaluable. His extensive network and comprehensive understanding of healthcare investment dynamics will likely play a pivotal role in shaping the company’s strategic initiatives and ensuring its resilience in the competitive landscape of behavioral health care.
In summary, Jason Bernhard’s tenure at Acadia Healthcare is poised to make a significant impact in the company’s pursuit of growth and enhanced shareholder value. His extensive expertise in investment banking and healthcare finance brings a wealth of knowledge that aligns with Acadia’s strategic objectives, making his role on the board not only timely but crucial for the organization’s future success. As the company navigates its current challenges, the leadership of individuals like Bernhard will be essential in steering Acadia Healthcare towards sustained growth and innovation in the behavioral health sector.